Picture loading failed.

Anti-SARS-CoV-2 Spike RBD therapeutic antibody (Pre-made Sotrovimab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Sotrovimab is an investigational monoclonal antibody therapy medication with activity against SARS-CoV-2. It is under development by GlaxoSmithKline and Vir Biotechnology, Inc.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-530-1mg 1mg 3090
GMP-Bios-ab-530-10mg 10mg 21890
GMP-Bios-ab-530-100mg 100mg 148000
GMP-Bios-ab-530-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-SARS-CoV-2 Spike RBD therapeutic antibody (Pre-made Sotrovimab biosimilar,Whole mAb)
INN Name Sotrovimab
TargetSARS-CoV-2 Spike RBD
FormatWhole mAb
Derivation
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Preregistration
Est. StatusActive
100% SI StructureNone
99% SI Structure7jx3:AB/6ws6:EF/6wps:CD:FG:HL/6wpt:DE:HL
95-98% SI StructureNone
Year Proposed2020
Year Recommendedna
CompaniesGlaxoSmithKline;Vir Biotechnology
Conditions Approvedna
Conditions ActiveCOVID-19
Conditions Discontinuedna
Development Techna